Decoy Therapeutics Inc. is a pre-clinical stage biotechnology company developing peptide conjugate therapeutics and small molecule drugs. The company utilizes its proprietary IMP3ACT platform, which integrates machine learning and artificial intelligence with high-speed synthesis techniques to engineer therapeutics targeting serious unmet medical needs. Its pipeline includes Designable Multi-Antivirals (D-MAVs) targeting respiratory viruses such as coronaviruses, paramyxoviruses, and filoviruses, as well as oncology candidates including the targeted protein degrader SP-3164 and the targeted protein inhibitor seclidemstat (SP-2577). The company previously operated as Salarius Pharmaceuticals, Inc. before completing a merger with Legacy Decoy in November 2025 and changing its name in January 2026. Decoy Therapeutics focuses on infectious diseases and oncology, creating adaptable medicines for emerging viral threats and undruggable targets.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage investors.decoytx.com
Sector Healthcare IR page investors.decoytx.com
Tags
peptide conjugates, antivirals, oncology, artificial intelligence, machine learning, protein degraders, respiratory viruses, coronaviruses, filoviruses, pre-clinical, IMP3ACT, D-MAV, SP-3164, seclidemstat, SP-2577, DCOY-CoV, Salarius Pharmaceuticals, Legacy Decoy
Press page —

Metrics

Valuation  
Market cap $ 4.699M
Market cap (USD) $ 4.699M
P/E —
PEG —
P/BV 1.03
P/S 2.55
P/OCF -0.51
P/FCF -0.87
Dividend yield —
Turnover / mcap —
Returns  
ROE -338.3%
ROI -212.6%
ROIC -160.6%
Profit margin —
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 23
Quality score -57.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue — — — 0 1.84M 5.233M 3.465M 838.142K 1.274M 1.011M — —
Net profit -12.518M -5.576M -12.543M -31.608M -12.768M -7.352M -6.936M -21.922M -34.434M -39.493M -29.142M —
Free cash flow -5.404M — — — -10.2M -10.314M — -23.599M -27.836M -32.611M -21.012M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 0.65 — — — — — — — — — — —
P/FCF -0.06 — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 12,181 10,385 9,939 0.00 3.86M 1.6M — — — —
↳ YoY growth -14.7% -4.3% -100.0% -58.5%
↳ 5y CAGR +165.3%
Cash and deposits (USD) 22.5M 19.3M 9.83M 3.74M 11.1M 29.2M 12.1M 5.9M 2.43M 10.7M
Cash flow detail
Operating cash flow (USD) -32.1M -27.7M -23.6M -11.6M -10.3M -10.2M -17.6M -12.8M -4.53M -4.83M
Purchases of property, plant and equipment (USD) -559,378 -113,498 0.00 0.00 -2,600 0.00 — — 0.00 -577,000
Change in receivables (cash effect) (USD) -12,181 1,796 7,206 690 0.00 — — — — —
Change in inventories (cash effect) (USD) -454,132 22,241 227,979 1,169 0.00 — — — — —
Change in payables (cash effect) (USD) 309,437 819,357 -1.66M -519,276 -2,782 -310,660 1.31M -2.26M 334,141 -1.17M
Dividends paid (cash effect) (USD) — — 0.00 -133,594 0.00 — — — — —
Interest paid (cash effect) (USD) — — 0.00 -9,005 -8,663 -1,468 0.00 -14,754 -10,643 -5,800
Share-based compensation (USD) 6.57M 4.22M 1.94M 751,618 319,391 559,044 796,803 524,838 273,730 219,058
Operating cash flow before change in receivables (USD) -32M -27.7M -23.6M -11.6M -10.3M — — — — —
Free cash flow (OCF - PPE - intangibles) (USD) -32.6M -27.8M -23.6M -11.6M -10.3M -10.2M — — -4.53M -5.4M
Income detail
Research and development expense (USD) 20.4M 17M 11.9M 4.02M 6.91M 8.55M 15.8M 7.17M 770,027 368,170
↳ 5y CAGR -11.5% -15.9% -1.4% -9.6% -28.1% -44.4%
Total comprehensive income (USD) -39.5M -34.4M -21.9M — — — — — — —
Comprehensive income to owners (USD) -39.5M -34.4M -21.9M — — — — — — —
Reported May 2, 2018 May 2, 2018 Mar 23, 2020 Mar 18, 2021 Mar 18, 2021 Mar 25, 2022 Mar 27, 2023 Mar 22, 2024 Mar 31, 2026 Mar 31, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Next-Generation D-MAVs™ Demonstrate Potent In Vitro Activity Against Ebola Zaire and Marburg Viruses; Targeting High-Value FDA Priority Review Voucher Eligibility

CAMBRIDGE, Mass., Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™) to target major respiratory and high consequence viral threats, today announced a refined corporate strategy to explore its D-MAVs for additional candidates, including a pan-filovirus program along the U.S. Food and Drug Administration (FDA) Animal Rule pathway for expedited regulatory approval. Based on recent encouraging discussions, the Company is actively pursuing non-dilutive government grants and public health partnerships to support the preclinical and clinical development of its broad-spectrum biodefense pipeline with monetization potential upon approval via Priority Review Voucher (PRV) opportunities.

Platform Velocity & Preclinical BreakthroughsFollowing the discovery of initial cross-viral activity from Decoy's pan-coronavirus fusion inhibitors against wild-type Ebola Zaire and Lassa fever virus (announced July 27, 2026), Decoy initiated a dedicated program to de novo design filovirus fusion inhibitors using its AI/ML-driven IMP³ACT™ computational engine. Key highlights include:

  • Ebola Zaire Potency: A first-generation de novo candidate achieved a low-micromolar half-maximal inhibitory concentration () of against wild-type Ebola Zaire virus in cell-based assays, a > five-fold improvement in potency vs. the pan-coronavirus lead, and a 7-fold improvement over the benchmark antiviral, remdesivir.

  • Marburg Virus Activity: This candidate also demonstrated potent cross-family activity against Marburg virus ().

  • Pan-Filovirus Objective: Decoy is executing generative design campaigns to establish a single, broad-spectrum pan-filovirus D-MAV for pre- and post-exposure prophylaxis against all human-infecting filoviruses.

Engineered for Extended Protection & Prophylactic UtilityEffective prophylaxis against high-consequence viral pathogens requires sustained drug levels at the site of infection ingress. Beyond optimizing binding potency, Decoy's IMP³ACT platform structurally engineers molecules for extended tissue residence time and long systemic plasma half-lives, with potential for weekly dosing.

Addressing the Filovirus Threat and Outbreak DynamicsFiloviruses, including the Ebola and Marburg viruses, cause severe hemorrhagic fevers with historical mortality rates between 40% and 90%. The ongoing outbreak of Bundibugyo virus highlights the critical vulnerability of existing therapeutics, which are largely single-strain specific.

Decoy's pan-filovirus approach targets the highly conserved helical fusion core shared across filovirus glycoproteins. By neutralizing the fundamental mechanism of viral entry, Decoy aims to deliver a unified prophylactic solution capable of protecting against Ebola Zaire, Marburg, Sudan, and Bundibugyo viruses simultaneously.

"Our recent filovirus data illustrate the speed and precision of our IMP³ACT platform," said Rick Pierce, Chief Executive Officer of Decoy Therapeutics. "In a single optimization cycle, we achieved potent activity against both Ebola Zaire and Marburg viruses. Crucially, by engineering our D-MAVs for extended residence time at key mucosal entry points, we are building therapies designed to offer durable protection. Advancing this program via the FDA Animal Rule path could allow us to efficiently address urgent biodefense needs through non-dilutive funding while expanding our multi-viral pipeline and proprietary computational database."

The Animal Rule Regulatory PathThe FDA's Animal Rule enables expedited approval for therapeutics targeting lethal pathogens where human efficacy trials are neither ethical nor feasible. Regulatory approval is established through well-controlled animal model efficacy studies combined with human safety and PK evaluation. This streamlined path significantly reduces clinical timelines and overhead, and positions successful candidates for government procurement and Strategic National Stockpile (SNS) inclusion. Decoy intends to fund its D-MAV filovirus and MERS programs primarily through non-dilutive government grants, industry and strategic biodefense partnerships.

In addition to addressing an urgent biodefense need, qualifying filovirus approvals offer substantial commercial value through the FDA's Tropical Disease Priority Review Voucher (PRV) Program:

  • Priority Review Voucher Eligibility: Filoviruses and Lassa fever are designated qualifying tropical diseases under FDA regulations. Upon FDA approval of an eligible filovirus candidate, Decoy would be eligible to receive a PRV.

  • Significant Non-Dilutive Capital Value: A PRV grants priority review status to a subsequent drug application or can be sold to another pharmaceutical company. Recent PRV market transactions have ranged between $100 million and $180 million, offering a major potential source of non-dilutive capital to drive corporate growth.

/C O R R E C T I O N -- Decoy Therapeutics, Inc/

In the news release, Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding, issued 22-Sep-2026 by Decoy Therapeutics, Inc over PR Newswire, we are advised by the company that the original version contained incorrect information introduced by PR Newswire during transmission. The complete, corrected release follows, with additional details at the end:

Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding

Next-Generation D-MAVs™ Demonstrate Potent In Vitro Activity Against Ebola Zaire and Marburg Viruses; Targeting High-Value FDA Priority Review Voucher Eligibility

CAMBRIDGE, Mass., Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™) to target major respiratory and high consequence viral threats, today announced a refined corporate strategy to explore its D-MAVs for additional candidates, including a pan-filovirus program along the U.S. Food and Drug Administration (FDA) Animal Rule pathway for expedited regulatory approval. Based on recent encouraging discussions, the Company is actively pursuing non-dilutive government grants and public health partnerships to support the preclinical and clinical development of its broad-spectrum biodefense pipeline with monetization potential upon approval via Priority Review Voucher (PRV) opportunities.

Platform Velocity & Preclinical BreakthroughsFollowing the discovery of initial cross-viral activity from Decoy's pan-coronavirus fusion inhibitors against wild-type Ebola Zaire and Lassa fever virus (announced July 27, 2026), Decoy initiated a dedicated program to de novo design filovirus fusion inhibitors using its AI/ML-driven IMP³ACT™ computational engine. Key highlights include:

  • Ebola Zaire Potency: A first-generation de novo candidate achieved a low-micromolar half-maximal inhibitory concentration (IC50) of 1.56 μΜ against wild-type Ebola Zaire virus in cell-based assays, a > five-fold improvement in potency vs. the pan-coronavirus lead, and a 7-fold improvement over the benchmark antiviral, remdesivir.

  • Marburg Virus Activity: This candidate also demonstrated potent cross-family activity against Marburg virus (IC50 = 1.04 μΜ).

  • Pan-Filovirus Objective: Decoy is executing generative design campaigns to establish a single, broad-spectrum pan-filovirus D-MAV for pre- and post-exposure prophylaxis against all human-infecting filoviruses.

Engineered for Extended Protection & Prophylactic UtilityEffective prophylaxis against high-consequence viral pathogens requires sustained drug levels at the site of infection ingress. Beyond optimizing binding potency, Decoy's IMP³ACT platform structurally engineers molecules for extended tissue residence time and long systemic plasma half-lives, with potential for weekly dosing.

Addressing the Filovirus Threat and Outbreak DynamicsFiloviruses, including the Ebola and Marburg viruses, cause severe hemorrhagic fevers with historical mortality rates between 40% and 90%. The ongoing outbreak of Bundibugyo virus highlights the critical vulnerability of existing therapeutics, which are largely single-strain specific.

Decoy's pan-filovirus approach targets the highly conserved helical fusion core shared across filovirus glycoproteins. By neutralizing the fundamental mechanism of viral entry, Decoy aims to deliver a unified prophylactic solution capable of protecting against Ebola Zaire, Marburg, Sudan, and Bundibugyo viruses simultaneously.

"Our recent filovirus data illustrate the speed and precision of our IMP³ACT platform," said Rick Pierce, Chief Executive Officer of Decoy Therapeutics. "In a single optimization cycle, we achieved potent activity against both Ebola Zaire and Marburg viruses. Crucially, by engineering our D-MAVs for extended residence time at key mucosal entry points, we are building therapies designed to offer durable protection. Advancing this program via the FDA Animal Rule path could allow us to efficiently address urgent biodefense needs through non-dilutive funding while expanding our multi-viral pipeline and proprietary computational database."

The Animal Rule Regulatory PathThe FDA's Animal Rule enables expedited approval for therapeutics targeting lethal pathogens where human efficacy trials are neither ethical nor feasible. Regulatory approval is established through well-controlled animal model efficacy studies combined with human safety and PK evaluation. This streamlined path significantly reduces clinical timelines and overhead, and positions successful candidates for government procurement and Strategic National Stockpile (SNS) inclusion. Decoy intends to fund its D-MAV filovirus and MERS programs primarily through non-dilutive government grants, industry and strategic biodefense partnerships.

In addition to addressing an urgent biodefense need, qualifying filovirus approvals offer substantial commercial value through the FDA's Tropical Disease Priority Review Voucher (PRV) Program:

  • Priority Review Voucher Eligibility: Filoviruses and Lassa fever are designated qualifying tropical diseases under FDA regulations. Upon FDA approval of an eligible filovirus candidate, Decoy would be eligible to receive a PRV.

  • Significant Non-Dilutive Capital Value: A PRV grants priority review status to a subsequent drug application or can be sold to another pharmaceutical company. Recent PRV market transactions have ranged between $100 million and $180 million, offering a major potential source of non-dilutive capital to drive corporate growth.

**About Decoy Therapeutics, Inc.**Decoy Therapeutics (NASDAQ: DCOY) is a biotechnology company developing Designable Multi-Antivirals (D-MAVs™) powered by its proprietary IMP³ACT™ platform. By combining generative AI structural design with advanced peptide-conjugate chemistry, Decoy creates single therapeutics that target conserved viral entry machinery across entire viral families. Decoy's pipeline includes programs targeting endemic coronaviruses for immunocompromised patients and MERS, paramyxoviruses (RSV, hPIV, Nipah, Measles), and filoviruses (Ebola, Marburg). For more information, visit decoytx.com.

Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding Decoy's strategy, preclinical development, regulatory approval pathways (including the FDA Animal Rule), non-dilutive funding, and potential dosing regimens, are forward-looking statements. These statements are based on current management expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that the Company will not obtain sufficient financing to execute on their business plans and risks related to Decoy's products and development plans, including unanticipated issues with any IND application process and the potential of the IMP3ACT™ platform. Readers are urged to carefully review and consider the various disclosures made by the Company in its reports filed with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, Decoy's actual results may vary materially from those expected or projected.

Contacts

Business Development

Peter Marschel, CBO

[email protected]

617-943-6305

Media Relations

Tara Mulloy, TMC Studio

[email protected]

978-855-5219

**Correction:**An earlier version of this release was missing information from the first two bullet points under "Platform Velocity & Preclinical Breakthroughs."

HOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) ("the Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced its entry into a warrant inducement agreement with an existing institutional investor of the Company for the immediate exercise of the Series B Milestone Warrants to purchase shares of the Company's common stock, for a total of 1,184,434 warrants (the "Existing Warrants"). The Existing Warrants were issued on June 29, 2026 and will be exercised at a reduced exercise price of $3.25 per share. In connection with the transaction, the exercise price of the Company's outstanding Series A Milestone Warrants and Series C Milestone Warrants will also be reduced from $5.91 per share to $3.25 per share. The exercise of the Existing Warrants will result in gross cash proceeds of approximately $3.85 million, before deducting placement agent fees and other transaction expenses. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

In consideration for the immediate exercise in full of the Existing Warrants, the investor will receive, in a private placement, new unregistered warrants to purchase up to 2,368,868 shares of the Company's common stock (the "New Warrants"). The New Warrants will have an exercise price of $3.25 and will be initially exercisable on the date that stockholder approval of the exercise of the New Warrants is obtained. The New Warrants will expire five years from the initial exercise date. The closing of the warrant inducement transaction is expected to occur on or about September 23, 2026, subject to satisfaction of customary closing conditions.

Curvature Securities LLC is acting as the sole placement agent in connection with this warrant inducement transaction.

The New Warrants described above were offered in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act") and, along with the common stock issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of common stock issuable upon exercise of the New Warrants.

Prompts

Decoy Therapeutics Inc. (ticker DCOY), listed in United States.

Company History

Date Change Detail
Feb 19, 2025 Renamed SALARIUS PHARMACEUTICALS, INC. → DECOY THERAPEUTICS INC.
Jul 23, 2019 Renamed FLEX PHARMA, INC. → SALARIUS PHARMACEUTICALS, INC.
— Former tickers SLRX

ETFs Holding Decoy Therapeutics Inc.

ETF Weight in ETF Shares Market value As of
MEDX 0.00% 20.75 $ 149.19 Jun 30, 2026